Diagnostics
The SomaSignal®
CardioDMTM test
Identify patients with type 2 diabetes more likely to experience a major acute cardiovascular event.*
Enable physicians to identify patients more likely to experience a major acute cardiovascular event (MACE)*
Through a single blood sample, our CardioDM test enables physicians to identify patients with type 2 diabetes (T2D) at risk of MACE and implement precision medical treatment, resulting in improved quality of care and fewer life-threatening events, at a lower cost to payers.
CardioDM test
Predicts the absolute risk of a cardiovascular event within 4 years with a median time-to-event of about 20 months, for patients over 40, with type 2 diabetes, with or without cardiovascular disease or chronic kidney disease
- Single blood test (55 µl)
- 27 protein biomarkers predict 4-year MACE with median time-to-event of about 20 months
- Discovery and validation in 6,514 patient samples > 30,000 years of follow-up
Cardiovascular disease is the leading cause of death and disability among people with type 2 diabetes1
1 out of 4 people…
Only 8%
of Type 2 Diabetic patients are taking guideline recommended cardioprotective (CP) medicines, regardless of their cardiovascular disease risk.2
31%
of Type 2 Diabetes patients are at high risk of cardiovascular disease.2
65%
of people with diabetes will die from some sort of heart disease or stroke – that’s 2x more likely as someone who doesn’t have the condition.4
800,000 deaths
More than 800,000 people in the U.S. die from cardiovascular disease each year — that’s 1 in every 3 deaths – and about 160,000 of them occur in people under age 65.5
2. Optum-United Health Group. Commercial and Medicare Advantage analysis of cardioprotective medication use in type 2 diabetic patients. Unpublished data analysis. August 2022.
4. American Heart Association and the Centers for Disease Control and Prevention (CDC) https://www.cdc.gov/diabetes/library/features/diabetes-and-heart.html
5. Centers for Disease Control and Prevention, Million Hearts® initiative https://millionhearts.hhs.gov/learn-prevent/cost-consequences.html#:~:text=Approximately%201.5%20million%20
Current standard of care for patients with type 2 diabetes
High-cost cardioprotective (CP) medication to all patients
Treat 60+ patients to avoid 1 MACE
Future standard of care for patients with type 2 diabetes
CardioDM test to all patients
Treat 20+ patients to avoid 1 MACE
What’s at stake?
Research shows there are three key barriers to identifying and and treating patients more likely to experience MACE.
Inaccurate or poor risk-stratification
Patients who should be – or could be – on CP therapy aren’t
Racial and socioeconomic barriers prevent equitable access to care
How CardioDM can help identify members more likely to experience MACE
Patients identified as high risk with the CardioDM test have been shown to have a 43.4% likelihood of a cardiovascular event or death within a 4-year time horizon, with a median time-to-event of about 20 months.6
| Current state of care | With the CardioDM test |
|---|---|
| Sub-optimal use of CP medications | Targeted/precise use of CP medications |
| Poor medication adherence to existing therapies | Improved adherence through identified urgency |
| Inefficient, low throughput, and high cost of existing diagnostics, post-symptom development | Efficient and high throughput for early detection |
| Limited biomarker information for physician, patient discussions | Holistic and patient-centric biomarker, diagnostic risk |
| Poor sensitivity to physiological change | Highly sensitive to patient behavioral modifications and medication upgrade |
See the evidence behind the SomaSignal CardioDM test
SomaSignal® tests are developed and their performance characteristics determined by SomaLogic Operating Co., Inc. They have neither been cleared or approved by the US Food and Drug Administration. SomaLogic operates a Clinical Laboratory Improvement Amendments (CLIA) certified, and College of American Pathologists (CAP) accredited laboratory